US EditionCStone Presents Preclinical Results of CS2011 (EGFR/HER3 bispecific antibody), CS5007 (EGFR/HER3 bispecific ADC), CS5005 (SSTR2 ADC) and CS5006 (ITGB4 ADC) at 2025 AACR
- CStone Pharmaceuticals presented preclinical data for four drug candidates—CS2011, CS5007, CS5005, and CS5006—at the 2025 AACR meeting in Suzhou, China on May 6, 2025.
- These drugs were developed using CStone's proprietary platforms combining machine learning-based bioinformatics and experimental validation to target tumor heterogeneity and specific antigens like EGFR, HER3, SSTR2, and ITGB4.
- CS2011 is an EGFR/HER3 bispecific antibody with high affinity and significant tumor-growth inhibition, CS5007 is an EGFR/HER3 bispecific ADC showing strong binding and internalization, CS5005 targets SSTR2 with robust antigen-dependent cytotoxicity, and CS5006 is a first-in-class ADC against ITGB4 displaying potent antitumor activity.
- Key data include CS5007 maintaining nearly 70% of its drug content after seven days in serum, the filing of a patent for CS5006 in April 2023, and ongoing extensive preclinical evaluations of all four candidates that support their advancement toward clinical development.
- These findings demonstrate CStone's advancement in developing potentially first-in-class or best-in-class anti-cancer therapies to address unmet medical needs both in China and globally.
Insights by Ground AI
Does this summary seem wrong?
66 Articles
66 Articles
All
Left
8
Center
19
Right
3
The Conway Daily Sun+65 Reposted by 65 other sources
CStone Presents Preclinical Results of CS2011 (EGFR/HER3 bispecific antibody), CS5007 (EGFR/HER3 bispecific ADC), CS5005 (SSTR2 ADC) and CS5006 (ITGB4 ADC) at 2025 AACR
SUZHOU, China, May 6, 2025 /PRNewswire/ -- CStone Pharmaceuticals ("CStone", HKEX: 2616), an innovation-driven biopharmaceutical company focused on anti-cancer therapies, announced today that poster presentations of preclinical data of CS2011 (EGFR/HER3 bispecific antibody), CS5007 (EGFR/HER3 bispecific ADC), CS5005 (SSTR2 ADC)…
Coverage Details
Total News Sources66
Leaning Left8Leaning Right3Center19Last UpdatedBias Distribution63% Center
Bias Distribution
- 63% of the sources are Center
63% Center
L 27%
C 63%
Factuality
To view factuality data please Upgrade to Premium
Ownership
To view ownership data please Upgrade to Vantage
